Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies

References

• Ralla B, Magheli A, Wolff I, et al. Prevalence of late-onset hypogonadism in men with localized and metastatic renal cell carcinoma. Urol Int. 2016.
   Web of Science ®Google Scholar
• Fleishman SB, Khan H, Homel P, et al. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol. 2010;28(34):5054–5060.10.1200/JCO.2010.30.3818
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England J Med. 2007;356(2):115–124.10.1056/NEJMoa065044
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.10.1200/JCO.2009.23.9764
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–562.10.1016/S1470-2045(13)70093-7
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England J Med. 2015;373(19):1814–1823.10.1056/NEJMoa1510016
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England J Med. 2007;356(2):125–134.10.1056/NEJMoa060655
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England J Med. 2007;356(22):2271–2281.10.1056/NEJMoa066838
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456.10.1016/S0140-6736(08)61039-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England J Med. 2013;369(8):722–731.10.1056/NEJMoa1303989
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet. 2011;378(9807):1931–1939.10.1016/S0140-6736(11)61613-9
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448–454.10.1038/sj.bjc.6604497
   PubMed Web of Science ®Google Scholar
• Garfield DH, Wolter P, Schoffski P, et al. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? J Clin Oncol. 2008;26(31):5131–5132; author reply 2-3.10.1200/JCO.2008.18.8680
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–769.
   PubMed Web of Science ®Google Scholar
• Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the european male ageing Study. J Clin Endocrinol Metab. 2010;95(4):1810–1818.10.1210/jc.2009-1796
   PubMed Web of Science ®Google Scholar
• Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009;117(1):38–43.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Vano YA, Oudard S, et al. Prognostic Impact of Baseline Serum C-Reactive Protein in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib. BJU international. 2013.
   Google Scholar
• Weickhardt AJ, Doebele RC, Purcell WT, et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013;119(13):2383–2390.10.1002/cncr.28089
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Johnson T, Choueiri TK, et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol. 2013;24(11):2927–2928.10.1093/annonc/mdt394
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412–1418.10.1200/JCO.2013.50.8267
   PubMed Web of Science ®Google Scholar